GSK has claimed approval in the EU for Exdensur, a long-acting respiratory drug that is considered one of its top growth prospects. The approval of Exdensur (depemokimab) for severe asthma and chronic ...
Investigators assessed whether exposure to O3, NO2, and fine particulate matter independently contributes to increased asthma exacerbation risk. Patients with mild asthma in the highest vs lowest ...
dNational Institute for Health and Care Research, Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Cambridge, UK eWellcome-Wolfson Institute for Experimental Medicine, School of Medicine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results